Data Sheet (Cat.No.T7312)

TargetMol

AX20017

Chemical Properties



CAS No. : 329221-38-7

Formula: C13H16N2O2S

Molecular Weight: 264.34

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AX20017, a small-molecule protein kinase G (PknG) inhibitor (IC50: 0.39 μM), functions by inhibiting the proliferation of M. tuberculosis.
Targets(IC50)	Antibacterial
In vitro	The inhibitory activity of AX20017 against the 11 known mycobacterial kinases revealed that the compound is highly selective for PknG . To test the activity of the inhibitor toward eukaryotic kinases, a screen of 28 different archetypical human kinases originating from six major protein kinase groups was set up. AX20017 did not affect the human kinases, whereas the activity of PknG was effectively inhibited[1].

Solubility Information

Solubility	DMSO: 32 mg/mL (121.06 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 3.3 mg/mL (12.48 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.783 mL	18.915 mL	37.8301 mL
5 mM	0.7566 mL	3.783 mL	7.566 mL
10 mM	0.3783 mL	1.8915 mL	3.783 mL
50 mM	0.0757 mL	0.3783 mL	0.7566 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Scherr N , Honnappa S , Kunz G , et al. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis[J]. Proceedings of the National Academy of Sciences, 2007, 104(29):12151-12156.

Rita Székely, Frigyes Wáczek, István Szabadkai, et al. A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signalling[J]. Immunology Letters, 2008, 116(2):225-231.